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Abstract
Retinal neurodegenerative diseases involve a scenario of inﬂammation and cell death that leads to morphological
alterations and visual impairment. Non-ocular inﬂammatory processes could affect neurodegenerative retinal disorders
and their progression, at least in part by activating microglial cells and releasing pro-inﬂammatory cytokines. Our
purpose was to study the consequences of a systemic inﬂammatory process in the progression of retinal degeneration
in P23H rats, a retinitis pigmentosa (RP) model. In order to induce a mild chronic systemic inﬂammation, we
administered low doses of lipopolysaccharide (LPS) from age P20 to P60 to dystrophic P23H rats and healthy SD rats.
Visual responsiveness was assessed by electroretinography (ERG). The morphological state of the retinas was analyzed
by ﬂuorescent immunohistochemistry (IHC), evaluating the number, morphology, and connectivity of different
neuronal populations by means of cell type-speciﬁc markers. Microglia density, distribution, and degree of activation
were evaluated by IHC and ﬂow cytometry. The expression levels of inﬂammation- and apoptosis-related genes were
analyzed by qRT-PCR arrays. Low-dose LPS administration did not induce signiﬁcant functional or morphological
changes in the retina of SD rats, although at the molecular level, we detected expression changes in genes related to
apoptosis. Otherwise, systemic injection of LPS into P23H rats induced a further deterioration in the ERG response, with
greater loss of photoreceptors and worsening of synaptic connectivity, accompanied by increasing numbers of
microglial cells, which also showed a more intense activation state. Several inﬂammation- and apoptosis-related genes
were upregulated. Our results indicate that chronic exacerbation of the inﬂammatory response in response to LPS
accelerates neurodegeneration in dystrophic P23H rats, suggesting that in patients with ocular neurodegenerative
diseases, peripheral damage, as a systemic infection or chronic inﬂammatory process, could accelerate disease
progression, and should be taken into account in order to select an appropriate therapy to revert, block or slow-down
the degenerative process.
Introduction
Retinal neurodegenerative diseases lead to morpholo-
gical and functional impairment within a scenario of
inﬂammation in which the three main cell death pathways
(apoptosis, necrosis, and autophagy) converge1–4. Micro-
glia activation and elevated levels of pro-inﬂammatory
cytokines are a common feature in neurodegenerative
disorders, such as Parkinson’s5,6, Alzheimer’s7,8, and
Huntington’s diseases or amyotrophic lateral sclerosis9.
Activated microglia release inﬂammatory mediators
steadily over time, which boosts the inﬂammatory cycle10.
Unlike the protective role of acute neuroinﬂammation,
chronic neuroinﬂammation mostly damages nervous tis-
sues11. Also, retinal neurodegenerative diseases, such as
retinitis pigmentosa (RP)3, age-related macular degen-
eration12, and glaucoma13,14 are concomitant with chronic
© The Author(s) 2018
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Nicolás Cuenca (cuenca@ua.es)
1Physiology, Genetics and Microbiology, University of Alicante, Alicante, Spain
2Optics, Pharmacology and Anatomy, University of Alicante, Alicante, Spain
These authors contributed equally: Agustina Noailles, Victoria Maneu.
Edited by A. Verkhratsky
Ofﬁcial journal of the Cell Death Differentiation Association
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
microglial activation and neuroinﬂammatory process.
Retinal microglial cells may also be activated by systemic
infection by fungus or virus15,16 and by immunosuppres-
sion or peripheral inﬂammation17, which could worsen
the degenerative process. However, the mechanisms by
which systemic inﬂammation and microglial activation
exert their effects on chronic neurodegeneration are not
yet widely understood.
Lipopolysaccharide (LPS) administration is commonly
used as a model of neuroinﬂammation18–20. LPS induces
microglial activation by a Toll-like receptor 4 (TLR4)-
dependent pathway, and is accompanied by the produc-
tion and release of pro-inﬂammatory cytokines, such as
interleukin (IL)-1β, IL-6 and Tumor necrosis factor alpha
(TNF-α), by the Mitogen-activated protein kinase
(MAPK) and Nuclear factor kappa beta (NF-kβ)
routes21,22. Systemic administration of LPS also activates
retinal microglia23,24, but the exact effect of LPS-activated
microglial cells on photoreceptor death and the
mechanisms underlying microglia–photoreceptor cross-
talk remain to be determined.
The main objective of this work was to elucidate whe-
ther a peripheral inﬂammatory process must be con-
sidered a risk factor in the progression of retinal
degenerative diseases. We studied the consequences of
systemic administration of LPS in P23H rats, an animal
model of RP. We decided to administer low doses of LPS
in order to trigger the alert status of microglia, but avoid a
massive inﬂux of pro-inﬂammatory cells to the retina, in
an attempt to mimic a mild chronic peripheral condition.
Our data suggest that peripheral inﬂammation exacer-
bates the inﬂammatory response in the retina and accel-
erates neurodegenerative events in the P23H rat model,
causing greater loss of photoreceptor numbers and
increased retinal dysfunction.
Materials and methods
Animals
Homozygous P23H line 3 rats, kindly provided by Mat-
thew LaVail (UCSF School of Medicine; www.ucsfeye.net/
mlavailRDratmodels.shtml), were used as a RP
model. Sprague–Dawley rats (SD) were used as a healthy
control group (Harlan Laboratories, Barcelona, Spain).
Twelve SD rats and 12 P23H rats were housed in
cages under controlled photoperiod (12-h light/12-h dark),
humidity (55–60%), and temperature (23 ± 1 °C) conditions.
Both food and water were provided ad libitum. All proce-
dures received prior approval from the ethics committee for
animal care and use at the University of Alicante (UA-07/
22/2013). The animals were treated according to current
guidelines and regulations for the use of laboratory animals
(NIH, ARVO and European Directive 2010/63/EU), in an
effort to minimize their suffering and limit the number of
animals used.
LPS administration
LPS was purchased from the Sigma-Aldrich laboratory
in St. Louis, MO (USA). A stock solution of 400 µg/ml
was prepared in saline and stored in aliquots of 1 ml at
−20 °C until administration. A total of six SD and six
P23H rats received three weekly injections of LPS intra-
peritoneally (i.p.) (60 µg/kg in saline) (LPS-injected rats),
whereas six SD and six P23H rats were used as control
groups receiving saline injections at the same time points
(vehicle-injected rats). Treatment began at P20 and con-
tinued until P60.
Electroretinographic (ERG) records
ERGs were performed under scotopic conditions at P60,
after completion of the treatments. Scotopic ﬂash-induced
ERG responses to light stimuli produced by a Ganzfeld
stimulator were recorded in both eyes. Light stimuli were
administered for 10ms at 11 increasing luminances,
ranging from −5.2 to 0 log cd s/m2. Between 3 and 10
consecutive recordings were averaged for each light level.
A 10-s interval was provided between ﬂashes in the case
of dim ﬂashes (−5.2 to −1.4 log cd s/m2), and up to 20 s
for the brightest ﬂashes (−0.8 to 0 log cd s/m2).
Immunohistochemistry
Histological studies were conducted at P60. Vertical
cryostat sections were prepared for immunostaining fol-
lowing procedures that have been well-established in the
literature25,26. The sections were incubated overnight with
the primary antibodies: monoclonal mouse anti-Bassoon
(1:1000; Enzo Life Sciences, Plymouth Meeting, PA, USA),
polyclonal rabbit anti-GFAP (1:50; Dako, Santa Clara,
USA), polyclonal rabbit anti-cone arrestin (1:500; Milli-
pore, Billerica, MA, USA), polyclonal rabbit anti-calbindin
(1:500; Swant, Bellinzona, Switzerland), polyclonal rabbit
anti-Iba1 (1:1000; Wako Chemicals, Richmond, VA,
USA), or monoclonal mouse anti-MHC class II RT1B
(clone OX-6, 1:200; AbD Serotec, Kidlington, UK). The
secondary antibodies employed were either Alexa Fluor®
555/488 anti-mouse or anti-rabbit IgG (1:100; Molecular
Probes, Eugene, OR, USA). Images were taken using a
Leica TCS SP2 confocal laser-scanning microscope (Leica
Microsystems). Images from SD and P23H sections were
parallel processed with Adobe Photoshop 10 software
(Adobe Systems Inc., San Jose, CA, USA).
Quantiﬁcation of microglial markers
To analyze microglial cells in each group of animals, we
examined vertical retinal sections. The quantity of cells
expressing either or both markers (Iba1+/MHC-II−, Iba1
−/MHC-II+ and Iba1+/MHC-II+) was determined at
×63 magniﬁcation. The data represent counts for the total
length of the section analyzed and were then extrapolated
to 1 mm of retinal tissue (as obtained through the ImageJ
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software; National Institutes of Health, Bethesda, MD,
USA). We analyzed at least two non-consecutive retinal
sections of each animal belonging to each experimental
group, including the optic nerve, and the counts are those
for the total length of each retinal section.
Quantiﬁcation of gliosis in Müller cells and astrocytes
To assess the response of Müller cells and astrocytes to
LPS administration, we quantiﬁed gliosis in Müller cells
and astrocytes using anti-glial ﬁbrillary acidic protein
(GFAP) antibodies. To do that, we analyzed four animals
per experimental group, evaluating in each retinal
section four equidistant regions in the temporal-nasal
axis: two in the temporal area (temporal-peripheral and
temporal-central) and two in the nasal area (nasal-per-
ipheral and nasal-central). Gliosis in Müller cells and
astrocytes were evaluated by measuring the ﬂuorescence
area related with GFAP immunostaining using the ImageJ
software.
Quantiﬁcation of photoreceptor rows, synaptic
connectivity, and structural integrity of cone
photoreceptors
To study retinal degeneration, we quantiﬁed photo-
receptor rows, using the nuclear marker TO-PRO 3, in
at least two non-consecutive retinal sections of each
animal. Quantiﬁcations were performed in six equidi-
stant regions in the temporal-nasal axis: three in the
temporal area (temporal-peripheral, temporal-medial,
and temporal-central) and three in the nasal area (nasal-
peripheral, nasal-medial, and nasal-central). An average
value of photoreceptor rows was calculated for each
animal.
We also evaluated synaptic connectivity in the outer and
inner plexiform layers (OPL/IPL) of the retina by mea-
suring the ﬂuorescence area associated with Bassoon
immunostaining using the ImageJ software. In all sections
analyzed, this quantiﬁcation was performed close to the
optic nerve. The structural integrity of cone photo-
receptors was evaluated by immunostaining with a poly-
clonal rabbit anti-cone arrestin antibody.
Flow cytometry
To identify microglial population and cell activation by
ﬂow cytometry, a retinal cell suspension was subjected to
a triple labeling with a cocktail of antibodies: anti-CD11b
conjugated to APC (allophycocyanin—Blue, clone M1/70;
eBioscience), anti-MHC Class II PE conjugated (phy-
coerythrin—Red, clone M5/114.15.2; Miltenyi Biotec,
Bergish Gladbach, Germany) and anti-CD45 FITC con-
jugated (clone 104.2, Miltenyi Biotec). Each rat retina was
analyzed individually. Data were acquired on a LSRFor-
tessa ﬂow cytometer (BD Biosciences) and analyzed using
FACSDiva software (BD Biosciences).
qRT-PCR arrays
To analyze the mRNA expression levels of genes asso-
ciated with apoptosis and inﬂammation pathways, we
used two commercial arrays from Qiagen® (Custom RT2
PCR Apoptosis array 96 wells; Qiagen, Hilden, Germany)
and Applied Biosystems (TaqMan® Inﬂammation Array
96 wells FAST plates; Applied Biosystems, Carlsbad, CA,
USA). Total RNA from retinas of vehicle- and LPS-treated
animals was obtained using the mirVana total RNA Iso-
lation kit (Ambion Ltd., Cambridgeshire, UK) and treated
with Turbo DNase (Ambion Ltd). Total RNA quantiﬁ-
cation was carried out using a Nanodrop-1000 device
(Thermo Fisher Scientiﬁc, Waltham, MA, USA). Two
hundred nanograms of total RNA from each sample were
reverse transcribed into complementary DNA (cDNA)
using the RT2 ﬁrst strand kit (Qiagen) and High Capacity
RNA-to-cDNA Kit (Applied Biosystems). We quantiﬁed
the mRNA expression levels of TNF-α, IL-1α, IL-1β,
Caspase-1, Caspase-8 and CX3CL1, p53, Bcl-2, Bad, Bax,
Hrk, and Apaf-1, GSK3β, Akt and mTOR. RNA18S, Actβ,
Hprt1, and Rpl13α were used as house-keeping genes.
RNA18S was used to normalize the analysis. Each run also
included negative controls. A StepOnePlus® system
(Applied Biosystems) was used to conduct PCR experi-
ments. The data analysis was performed using
the ΔΔCt based calculations using free array data
analysis web portal software, provide by Qiagen®. Data
obtained from Applied Biosystems arrays were analyzed
using the ExpressionSuite software (www.thermoﬁsher.
com/es/es/home/technical-resources/software-downloads/
expressionsuite-software.html) with the same calculation
method.
Statistical analysis
SPSS 20.0 software (IBM, Armonk, NY, USA) was used
to perform the statistical analysis and a Multivariate
Analysis of Variance (MANOVA) was calculated to assess
the effects of LPS administration. A Bonferroni’s test was
used to perform post-hoc pairwise comparisons when the
signiﬁcance level was found to be 0.05. All the analyzed
categories exhibited normal distributions and homo-
geneity of variance. Statistical signiﬁcance was established
at P < 0.05. The data were subsequently plotted as the
mean ± SEM.
Flow cytometry results were analyzed using Student’s
t-tests to compare values in different animal groups. Results
were expressed as the mean ± standard deviation and were
considered to be statistically signiﬁcant at P < 0.05.
Results
The effects of systemic LPS administration on ERG retinal
responses
To assess the effect of low-dose systemic LPS in the
functional activity of the retina of P23H and SD rats, ERG
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responses induced by scotopic ﬂash were recorded in four
animal groups (vehicle-injected SD, LPS-injected SD,
vehicle-injected P23H, and LPS-injected P23H; n= 6 in
each group). As shown in Fig. 1, chronic administration of
LPS to P23H rats reduced the ERG response to light ﬂa-
shes. The maximum a- and b-wave amplitudes registered
were 31% and 33% lower (respectively) in LPS-injected
P23H rats than that observed in vehicle-injected dys-
trophic animals (57.7 ± 1.7 μV and 38.3 ± 1.2 μV for the a-
wave, 342.2 ± 5.1 μV and 227.7 ± 4.5 μV for the b-wave;
analysis of variance (ANOVA), Bonferroni’s test, P <
0.001, for both cases; Fig. 1). The same doses of LPS did
not affect the retinal response of SD rats.
The effects of systemic LPS administration on the number
of photoreceptor rows, structural integrity of cone
photoreceptors, and synaptic connectivity
The analysis of retinal sections of each animal group
stained with TO-PRO 3 revealed that the retinas of
vehicle-injected P23H animals had an average of 7.7 ± 1.1
rows of photoreceptors, whereas vehicle-injected SD rats
showed an average of 11.1 ± 0.8 photoreceptor rows
Fig. 1 Effect of LPS on functional changes associated with retinal degeneration. a Representative scotopic full-ﬁeld ERG waveforms from P60
SD and P23H rats injected with vehicle or LPS from P20 to P60. Units on the left show input ﬂash intensities in log cd s/m2. b, c Luminance-response
curves for mixed scotopic b-waves b and a-waves c from vehicle-injected SD rats (black dots), LPS-injected SD rats (white dots), vehicle-injected P23H
rats (black squares), and LPS-injected P23H rats (white squares). Data are represented as mean ± SEM, n= 6. *P < 0.05, ***P < 0.001; ANOVA,
Bonferroni’s test
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(Fig. 2). The systemic administration of LPS did not
induce a signiﬁcant reduction of photoreceptor rows in
SD rats, whereas the same LPS dose reduced by 45% the
number of photoreceptor rows in P23H rats (4.2 ± 0.8
rows; ANOVA, Bonferroni´s test, P < 0.001). This reduc-
tion in the quantity of photoreceptor rows was evident in
all retinal sections analyzed (data not shown).
We also evaluated the number, shape, and structural
integrity of cone photoreceptors in the retinas of each
experimental group, using antibodies against cone arrestin.
In SD rats, the administration of LPS did not provoke
signiﬁcant differences in morphology or number of cone
photoreceptors (Figs. 3a, b). In vehicle-injected P23H rats,
cones showed inner and outer segments than were shorter
than those observed in SD rats (Figs. 3a, c). But cone
photoreceptors experienced more drastic changes in LPS-
treated P23H rats. In these animals, the cones were very
small, with short and swollen outer segments (Fig. 3d). The
axons were missing entirely, and the pedicles emerged
directly from the cone cell bodies. The number of cone
photoreceptors was also smaller in LPS-treated P23H rats
than in vehicle-treated P23H rats (60 ± 2.5 cones/mm and
109 ± 2 cones/mm, respectively; ANOVA, Bonferroni’s test,
P < 0.001, n= 6 in both cases; Fig. 3e).
Fig. 2 Effect of LPS on the number of photoreceptor rows. Representative images of vertical retinal sections from SD a, b and P23H rats d, e
injected with vehicle a, d or LPS b, e. Nuclei were stained with TO-PRO 3 (blue). c, f Average number of photoreceptor rows along central sections of
the retina in vehicle- and LPS-injected SD rats c and P23H rats f. Data are represented as mean values ± SEM, n= 6 in each condition. ***P < 0.001;
ANOVA, Bonferroni’s test. ONL outer nuclear layer, INL inner nuclear layer, GCL ganglion cell layer. Scale bar, 20 μm
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Given the signiﬁcant decrease in the number of pho-
toreceptor rows in P23H rats administered LPS, synaptic
connections were assessed in the retina of dystrophic and
normal animals. The analysis of retinal sections immu-
nostained with polyclonal rabbit anti-calbindin antibodies
showed no signiﬁcant differences in the average number
of horizontal cells between P23H or SD rats administered
LPS or vehicle (Supplementary material 1). However, in
LPS-injected P23H rats the dendritic arborization of
horizontal cells was clearly degenerated as compared with
vehicle-injected P23H rats (Fig. 4). Numerous Bassoon-
immunopositive spots were observed at the INL level in
P23H animals, regardless of whether they were adminis-
tered LPS. By contrast, few synaptic ribbons were
observed at the OPL in P23H rats injected with LPS
(Fig. 4d), thus revealing that presynaptic contacts between
photoreceptors and bipolar/horizontal cells were reduced
in these animals.
To quantify the differential expression of Bassoon, we
obtained the proﬁle plots of mean gray intensity in each
horizontal line of images of the retina showing Bassoon
immunoﬂuorescence (Figs. 5a, b). As it is shown in Fig. 5c,
Fig. 3 Effect of LPS on the number and integrity of cone photoreceptors. a–d Confocal images of representative vertical retinal sections
showing the cone morphology after immunostaining with antibodies against cone arrestin (green) in SD a, b and P23H rats c, d, vehicle-injected a, c
and LPS-injected b, d. Nuclei were stained with TO-PRO 3 (blue). e Quantiﬁcation of cone photoreceptors per mm of retina in P23H vehicle- and LPS-
injected rats. Data are represented as mean values ± SEM, n = 6. ***P<0.001; ANOVA, Bonferroni’s test. GCL ganglion cell layer, INL inner nuclear layer,
ONL outer nuclear layer. Scale bar, 40μm
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the mean area of the proﬁles obtained at the OPL level in
vehicle-injected P23H rats were signiﬁcantly higher (3.5-
fold greater) than those obtained in P23H rats adminis-
tered LPS (11200 ± 500 pixels and 3500 ± 150 pixels,
respectively; ANOVA, Bonferroni’s test, P < 0.001, n= 6
in both cases). No signiﬁcant differences were observed at
the IPL (Fig. 5d, 15500 ± 700 pixels and 14500 ± 850
pixels, respectively). In the SD rat groups, we did not ﬁnd
any signiﬁcant differences in the ﬂuorescent area of either
plexiform layer (data not shown).
The effects of systemic LPS administration on retinal
microglial number and activation state
In SD rat retinas, Iba1+ cells were distributed in the
inner and outer plexiform and ganglion cell layers
(Fig. 6a) and showed negligible immunoreactivity against
MHC Class II antibodies (Figs. 6b, c). In these animals,
LPS injection did not induce any differences in the mor-
phology, activation state, density, or distribution of retinal
microglial cells (Figs. 6d–f). In P23H retinas, microglial
cells were seen in all retinal layers, and were present in
greater numbers in IPL and OPL (Figs. 6g–i), in a density
higher than that observed in SD rats (11.8 ± 1 Iba1+ cells/
mm and 7.7 ± 0.5 Iba1+ cells/mm, respectively; ANOVA,
Bonferroni’s test, P < 0.01, n= 6, in both cases; Fig. 7a).
Moreover, P23H rat retinas presented ameboid Iba1+
cells, some of them exhibiting the activation marker
MHC-II (Figs. 6g–i). LPS injection in P23H rats increased
the quantity of Iba1+ cells, many of them showing ame-
boid shape and expressing MHC-II (Figs. 6j-l). Quanti-
tative analysis of the retinal sections showed that in LPS-
injected P23H rats the relative quantity of Iba1+/MHC-II
− cells was 12% higher than that observed in vehicle-
injected P23H rats (ANOVA, Bonferroni’s test, P < 0.05;
Fig. 7b). The number of double immunoreactive cells Iba1
+/MHC-II+ was also signiﬁcantly higher in LPS-injected
P23H animals when compared with P23H rats (35% more;
ANOVA, Bonferroni´s test, P < 0.001; Fig. 7b).
In addition to the morphological and quantitative ana-
lysis of retinal sections, retinal cells expressing the
microglia marker CD11b were identiﬁed by ﬂow cyto-
metry (Figs. 8a, b) and MHC-II and CD45 expression was
measured to determine their level of activation (Figs. 8a,
c). SD rats showed no signiﬁcant differences in the
number of retinal CD11b+ cells between LPS- and
vehicle-injected animals (0.8 ± 0.2% in vehicle-injected vs.
Fig. 4 Effect of LPS on synaptic connectivity between photoreceptors and horizontal cells. High magniﬁcation confocal images of retinal
sections showing synaptic contacts and dendritic arborization of representative horizontal cells after immunostaining with antibodies for horizontal
cells (calbindin, green) and synaptic ribbons (Bassoon, red) in SD a, b and P23H rats c, d, administered with vehicle a, c or LPS b, d. Nuclei were
stained with TO-PRO 3 (blue). INL: inner nuclear layer, OPL: outer plexiform layer, ONL: outer nuclear layer. Scale bar 10μm.
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0.9 ± 0.2% in LPS-injected animals, Fig. 8b). Between these
groups, the amount and distribution of different pheno-
types of microglial cells also did not show any differences.
Otherwise, P23H retinas showed an increased CD11b+
microglial population (4.0 ± 1.2%) with respect to SD rat
retinas (Student’s t-test, P < 0.001; Fig. 8b). The quantity
of CD11b+ cells was not signiﬁcantly different between
P23H rats injected with vehicle or LPS, but the ﬂuores-
cence intensity for CD11b and CD45 was signiﬁcantly
higher in LPS- injected vs. vehicle-injected P23H rats
(Student’s t-test, P < 0.01 and P < 0.001, respectively;
Fig. 8c).
The effects of systemic LPS administration on astrocytes
and Müller cells
The expression of GFAP in healthy rat retinas is
restricted to astrocytes within the inner retina3. However,
under many pathological conditions or retinal damage,
Müller cells are found to express GFAP3,27. Using anti-
GFAP antibodies, we assessed the response of Müller cells
and astrocytes to LPS treatment (Fig. 9). In vehicle-
injected SD rats, GFAP immunoreactivity was virtually
limited to the inner margin of the retina, colocalizing with
astrocytes, whereas P23H rat retinas also showed GFAP
immunoreactivity in Müller cells, which exhibited a
marked labeling throughout the entire cell. In both
strains, SD and P23H rats, LPS injection triggered an
increase in GFAP immunoreactivity in the Müller cell
processes as compared with vehicle-injected animals
(37652 ± 2000 pixels and 18296 ± 3100 pixels, respec-
tively, in SD animals and 71655 ± 1500 pixels and 55185 ±
1220 pixels, respectively, in P23H animals; ANOVA,
Bonferroni’s test, P < 0.001, n= 4 in both cases;
Figs. 9a–e). LPS treatment also triggered an increase in
GFAP immunoﬂuorescence in the inner margin of the
retina, colocalizing with astrocytes and end feet of Müller
cells (68834 ± 1900 pixels and 29613 ± 1500 pixels,
respectively, in SD animals and 86308 ± 4500 pixels and
Fig. 5 Effect of LPS on synaptic connectivity. a, b Representative vertical retinal sections showing synaptic ribbons immunostained with anti-
Bassoon antibodies (red) from vehicle-injected a and LPS-injected b P23H rats. Right inserts show the proﬁle plots of mean gray intensity for each
horizontal line of images of the retina showing Bassoon immunoﬂuorescence. c, d Quantiﬁcation of the differential expression of Bassoon in the
outer c and the inner plexiform layers d of P23H rats. Data are represented as mean values of ﬂuorescence in areas close to the optic nerve ± SEM, n
= 6. ***P < 0.001; ANOVA, Bonferroni’s test. IPL: inner plexiform layer, OPL: outer plexiform layer. Scale bar 40μm.
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Fig. 6 Effect of LPS on retinal microglia in SD and P23H rats. Representative vertical retinal sections immunostained with antibodies against Iba1
(green) and MHC-II (red) in vehicle- and LPS-injected SD rats a–f, or vehicle- and LPS-injected P23H rats g–l. Arrows point microglia MHC-II-
immunopositive cells. Nuclei were stained with TO-PRO (blue). All images were taken in the central retina. GCL ganglion cell layer, IPL inner plexiform
layer, OPL outer plexiform layer. Scale bar 40μm
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62251 ± 2600 pixels, respectively, in P23H animals;
ANOVA, Bonferroni’s test, P < 0.001, n= 4 in both cases;
Fig. 9f).
The effects of systemic LPS administration on the retinal
expression of inﬂammation- and apoptosis-related genes
We analyzed the mRNA expression levels of genes
related to apoptosis and inﬂammatory processes by
quantitative RT-PCR, as well as genes involved in reg-
ulatory pathways. Table 1 shows normalized relative
mRNA levels (fold change) of the selected genes in the
retina of each experimental group, compared with the
expression level found in vehicle-injected SD rats. Sys-
temic LPS injection in SD rats increased the retinal
expression of Caspase-8 (11-fold) and the apoptosis-
related genes Bad (4), Bax (8), Hrk (7), Bcl-2 (10), Apaf-1
(19) and p53 (9). In the retina of these animals, we also
detected increased expression levels of GSK3β (8), alto-
gether with Akt (10) andmTOR (1.6) (Fig. 10a). In vehicle-
injected P23H rats, we saw increased retinal expression of
the inﬂammation-related genes TNF-α (5), IL-1α (6), IL-
1β (3), Caspase-1 (7) and Caspase-8 (40), and also of the
regulatory genes GSK3β (22), Akt (12), and mTOR (5). In
this experimental group, the retinal expression levels of
apoptosis-related genes were: Bad (17), Bax (6.5), Hrk (1),
Bcl-2 (3), Apaf-1(225), and p53 (13), whereas CX3CL1
levels were reduced (0.6) (Fig. 10c). In dystrophic P23H
rats, the systemic injection of LPS induced greater chan-
ges in retinal mRNA expression than that observed in SD
rats, affecting genes related to both inﬂammation and
apoptosis pathways: Bad (24), Bax (10000), Hrk (16), Bcl-2
(59), Apaf-1(3) and p53 (23), CX3CL1 (2.5); TNF-α (3800),
IL-1α (240), IL-1β (38), Caspase-1 (30), and Caspase-8
(23). The expression levels of regulatory genes were
GSK3β (100), Akt (1213) and mTOR (4) (Fig. 10b). When
comparing the expression levels of these genes in P23H
LPS-injected rats with P23H vehicle-injected rats, the
relative expression levels in the former were: Bad (1.4),
Bax (1600), Hrk (16), Bcl-2 (17), p53 (2), CX3CL1 (3);
TNF-α (740), IL-1β (42), IL-1β (11), Caspase-1 (4),
Caspase-8 (0.6); GSK3β (4.5), Akt (0.1), and mTOR (0.8)
(Fig. 10d).
Discussion
The potential inﬂuence of systemic pathologies in the
progression of retinal neurodegenerative diseases is a
crucial issue to be explored due to its expected inﬂuence
on the prognosis and therapy. Our main objective was to
assess whether peripheral inﬂammatory conditions can
worsen the progression of neurodegeneration in an ani-
mal model of RP. In order to mimic the effect of a mild
chronic condition, we chronically administered low doses
of LPS, which did not induce physiological or morpho-
logical changes in healthy retinas.
LPS-induced systemic inﬂammation aggravates
morphological and physiological disturbances in
dystrophic retinas
Compared with healthy rat retinas, P23H transgenic rat
retinas showed a decreased number of photoreceptors and
synaptic contacts, as well as lower ERG responses. Her-
editary retinal degeneration was accompanied by microglial
activation, evidenced by increased microglial density and
higher expression levels of microglial activation markers.
This is in agreement with previous ﬁndings showing that
neurodegenerative retinal diseases are linked to chronic
Fig. 7 Effect of LPS on microglia cell number assessed by immunohistochemistry. Quantiﬁcation of microglial cells in retinas from SD and P23H
rats injected with vehicle or LPS after immunostaining with anti-Iba1 and anti-MHC-II antibodies. The ﬁgure shows the average of total Iba1-
immunopositive cells a and the average of microglial cells showing the phenotypes Iba1+/MHC-II−, Iba1+/MHCII+ and Iba1−/MHC-II+ b. Data are
presented as mean values ±SEM, n = 6. **P<0.01; ANOVA, Bonferroni’s test. Different letters indicate statistical signiﬁcance
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microglial activation and neuroinﬂammation3,4,28,29. Acti-
vated microglia mediate neuroinﬂammation by releasing
several pro-inﬂammatory molecules including cytokines,
chemokines, trophic factors, and small molecules, which
promote and perpetuate the inﬂammatory response,
potentially leading to neurodegeneration3,10,30–32.
As a result of repeatedly administering low doses of LPS
to P23H degenerating retinas, a further dramatic decrease
in the quantity of photoreceptor cells and synaptic con-
nectivity in the OPL was observed, in agreement with the
lower ERG responses observed in this experimental
group. Speciﬁcally, it has been demonstrated that systemic
inﬂammation induced by LPS increases neuronal apop-
tosis in the brain of an animal model of prion disease33.
Hippocampal-dependent learning deﬁcits are triggered by
LPS-induced peripheral inﬂammation in elderly rats34,
and repeated challenges with LPS cause increased
Microtubule associated protein (MAP, Tau) hyperpho-
sphorylation in a transgenic model of Alzheimer’s dis-
ease35. SD control rats administered with the same doses
of LPS failed to show retinal changes at either a structural
or physiological level.
LPS-induced systemic inﬂammation triggers microglial
activation and gliosis in dystrophic retinas
The LPS-induced microglial activation observed in
P23H rat retinas is in agreement with our previous works
and those by others, showing that systemic infections
caused by cytomegalovirus15 or Candida albicans16, as
well as peripheral insults17 are capable of triggering
microglial activation and increasing the quantity of
microglial cells in the retina. The higher number of Iba1-
positive cells in the retina of LPS-injected P23H rats could
be caused by migration of inﬂammatory macrophages,
Fig. 8 Effect of LPS on retinal microglial cell number and activation state, assessed by ﬂow cytometric analysis. a Representative forward
scatter (FSC) vs. CD11b dot plots, in which CD11b-positive cells are gated and double dot plots showing MHC-II vs. CD11b and CD45 vs. CD11b of
CD11b-immunopositive cells. Each dot plot is representative of a minimum of four independent replicates. In all, 106 events were recorded per
sample and 500,000 events are represented. The percentage of CD11b-immunopositive population is indicated. b Mean values of CD11b-
immunopositive population in vehicle-injected and LPS-injected SD and P23H rats. c Histograms representing mean ﬂuorescence intensity values of
the CD11b-positive population labeled with anti-CD45, anti-MHC-II, and anti-CD45 antibodies (106 cells were analyzed in each assay) in both P23H
experimental groups. Data are presented as mean values ± SEM. **P < 0.01, ***P < 0.001; Student’s t-test
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myeloid precursors, or inﬂammatory monocytes, or by the
proliferation of retinal microglia, as these cell types are
able to proliferate in situ once they have differentiated36.
In a previous work, we evidenced the presence of pro-
liferative Iba1+ cells in P23H rat retinas, but not in
healthy control rats, suggesting that increases of Iba1-
positive cells in P23H rats is accomplished, at least par-
tially, by the in situ proliferation of resident microglia4.
In this study, we show that LPS injection induces an
increase in GFAP immunoreactivity in the Müller cell
processes in the inner margin of the retina of P23H rats.
A hallmark of gliosis is the upregulation of intermediate
ﬁlament proteins in glial cells, including GFAP. Thus,
our results suggest that low-dose LPS treatment
exacerbates reactive gliosis in astrocytes and Müller
cells.
Fig. 9 Effect of LPS on retinal Müller cells and astrocytes. a, b Representative vertical retinal sections from vehicle-injected a, c and LPS-injected
b, d SD a, b and P23H c, d rats immunostained with anti-GFAP antibodies (green). Nuclei were stained with TO-PRO (blue). Note the reactive changes
in astrocytes and Müller cells associated with LPS administration in both SD and P23H rats. e, f Quantiﬁcation of GFAP immunostaining in the Müller
cell processes e and the inner margin of the retina f, colocalizing with astrocytes and end feet of Müller cells. Data are represented as mean values of
ﬂuorescence in pixels ± SEM, n= 4 in each condition. ***P < 0.001; ANOVA, Bonferroni’s test. Scale bar 20μm
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Systemic inﬂammation exacerbates inﬂammatory and
apoptotic pathways in dystrophic retinas
At the molecular level, low-dose LPS treatment in SD
rats induced upregulation of several important apoptosis-
related genes, involved in both death and survival signals
(Bcl-2, Bax, Hrk, p53, Apaf-1, and Caspase-8), which can
be associated with an early cellular response. In this
experimental group, we could not detect any increased
expression of inﬂammation-related genes. This result is
consistent with the normal appearance of these retinas,
and probably due to the low doses of LPS we used. As we
did not detect any functional nor morphological change in
the retinas, we assume that retinal cells were able to
maintain cellular homeostasis. P23H rat retinas showed
increased expression levels of several inﬂammation-
related genes (Tnf-α, Il-1α, Il-1β, Caspase-1, and
Caspase-8) in agreement with the higher inﬂammatory
state of the degenerating retina that is observed during all
the degenerative process, compared with healthy retinas4.
This result also agrees with the high levels of pro-
inﬂammatory cytokines present in certain neurodegen-
erative diseases, such as Parkinson’s6,37, Alzheimer’s7,8,
and Huntington’s diseases or amyotrophic lateral sclero-
sis9. In P23H rat retinas, we also detected increased levels
of expression of genes associated with apoptosis (p53, Bcl-
2, Bad, Bax, and Apaf-1), in concordance with the
enhanced rate of apoptosis observed in this work and in
previous published studies38. In P23H rats, LPS treatment
induced a drastic further increase in the expression of
inﬂammation- and apoptosis-related genes, which agrees
Fig. 10 Schematic view showing relative expression levels of cell mediators in our experimental conditions and the interactions between
and their effects on autophagy, necroptosis, inﬂammation, and apoptosis as described by others (see text for references). a–c Relative
expression (fold change, in red squares) of mRNA in the retina of LPS-injected SD rats a, LPS-injected P23H rats b and vehicle-injected P23H rats c,
compared with the expression levels found in vehicle-administered SD rats. d Normalized expression of mRNA in LPS-injected P23H rats, compared
with that found in vehicle-administered P23H rats. The relative size of the letters represents the relative level of gene expression
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with other authors’ results showing that systemic
administration of LPS, even in a single dose, causes
increased microglial activation, inﬂammatory exacerba-
tion, and enhanced neurodegeneration through increased
production of TNF-α, IL-1β, and IL-6 in the brain39,40. In
P23H model of retinal degeneration, an increased
expression of Tnf-α, Il-1α, and Il-1β could, at least in part,
explain the increased loss of photoreceptors observed in
LPS-injected P23H rats3,10,30–32,41–43. In LPS-injected
P23H rats, we found further upregulation of the
Caspase-1 gene, pointing to a scenario of even greater
apoptosis and inﬂammation44–46.
In agreement with the accepted main role of p53 in
neuroinﬂammatory processes in neurodegeneration47, in
our experimental conditions, the transcription factor p53
also appears as a key factor in the neurodegenerative
process. p53 expression was enhanced in all the
conditions tested, with higher increases in P23H rat
retinas than in LPS-injected SD rat retinas, and even
higher expression levels in the retinas of LPS-injected
P23H rats. Hence, in our experiments, the response
obtained with repeated low doses of LPS reinforce
the idea that a chronic inﬂammatory peripheral
state does affect the degenerative process by increasing
the expression of inﬂammation- and apoptosis-related
markers.
Concordant to its activity as an early modulator in
damaged tissues48–51, Caspase-8 expression levels were
increased in all our experimental groups (SD LPS-injec-
ted, P23H vehicle-injected, and P23H LPS-injected).
The activation of TLR4 by LPS can participate in cell
apoptosis through the phosphatidylinositol 3 kinase/
AKT/GSK3β signaling pathway52. In our experiments,
LPS administration in low doses to SD rats provoked an
imbalance between pro-death and pro-survival signals can
be determinant for the ﬁnal outcome of the cell. Addi-
tionally, the Akt, Glycogen Synthase Kinase 3 beta
(GSK3β), and Mammalian Target of Rapamycin (mTOR)
signaling pathways have been implicated in the ﬁnal
outcome of threatened cells52–59. Inhibitors of Glycogen
Synthase Kinase 3 beta (GSK3β) provide potential ther-
apeutic strategies to control inﬂammation60, and are thus
drugs that may potentially be used for the treatment
of RP61.
Fig. 11 Schematic representation of the hypothetical contribution of death pathways to the outcome of the cell in different noxious
situations in animal retinas: a chronic administration of low doses of LPS (from P20 to P60) to SD healthy rats, b genetically determined retinal
dystrophy (P23H rat model of RP), and c chronic administration of low doses of LPS to the genetically determined dystrophic rats (P23H model). Our
results indicate that in healthy retinas, low doses of LPS induce expression changes in pro- and anti-death signals, as well as in apoptosis-related
transcripts, although no signs of cell death are observed. In P23H rat retinas, increased expression levels of genes related to apoptosis and
inﬂammation and pro-death signals alter the balance between pro-survival and pro-death signals and inﬂuence the death scenario observed at P60.
In this model of degeneration, the administration of low doses of LPS probably induces an increase in necroptotic cell death, together with
insufﬁcient autophagic mechanisms that would worsen the retinal degenerative process and contribute to the exacerbation of the morphological
and functional damage, concordant with the morphological worsening and loss of function observed
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Our results revealed that LPS administration induced
increased expression levels of mTOR in the retina of SD
rats, in agreement with other works that attribute to
mTOR a main role in the inﬂammatory effects of
LPS58,62,63. The expression levels of mTOR were higher in
both P23H rat groups, which could contribute to the
increased degeneration observed in these animals, as
previously described for retinal degenerative processes59.
We hypothesize that the effects of LPS may alter the
balance between pro-survival and pro-death signals and
exacerbate the cell death processes (Fig. 11).
Systemic LPS can modify death pathways contribution to
the degenerative process in dystrophic retinas
In this death scenario, the contribution of other death
pathways as necroptosis and autophagy should be taken
into account. When compared with vehicle-injected P23H
rat retinas, the retinas of P23H rats injected with LPS
showed an enhanced death stimulus, with dramatically
increased expression levels of Tnf-α and p5351,64. As both
apoptosis and necroptosis can be triggered simultaneously
in the retina65,66, these data, together with the down-
regulation of Caspase-8, and the reduced expression of
the pro-apoptotic Apaf-1 in these animals, leads us to
hypothesize that LPS trigger the activation of necroptosis
pathways in the retina of dystrophic rats. Necroptosis cell
death would contribute to the augmented inﬂammatory
response in the retina of these animals and to the wor-
sening of the morphological and functional activity.
This hypothesis agrees with prior studies showing that
retinal microglia undergo RIP1/3-mediated necroptosis in
rd1 mouse model of retinal neurodegeneration
and also after an acute retinal neural injury67. Necroptotic
microglia release large amounts of pro-inﬂammatory
cytokines, such as TNF-α, in response to LPS or oxida-
tive stress, triggering neuroinﬂammation and, conse-
quently, exacerbating retinal damage and disease
progression67.
Previous studies showed that LPS treatment can pro-
mote autophagy in microglia and macrophages68,69.
In our experiments, LPS administration to P23H
dystrophic rats induced increased levels of Beclin-1 and
Bad expression and reduced expression levels of
mTOR. These results suggest a higher degree of autop-
hagy processes70. But the higher levels of Bax, Bcl-2, and
p5331,70–76 seem to point to the fact that, despite the
increased pro-autophagy markers apoptotic and inﬂam-
matory state in these animals is dampening the
activation of appropriate autophagy mechanisms. Autop-
hagy dysfunction has been related to a number of neu-
rodegenerative diseases, such as Alzheimer’s or
Parkinson’s diseases, among other neuron-affecting
pathologies7,9,69,77,78.
In the degenerating retinas of P23H rats treated with
LPS, the insufﬁcient autophagy together with the pro-
motion of necroptotic cell death would worsen the
degenerative process and contribute to the exacerbation
of the morphological and functional damage.
Conclusions
All these data indicate that administering low doses of
LPS to dystrophic P23H rats exacerbates inﬂammatory
and apoptotic states, accelerates the loss of cone pho-
toreceptors and retinal functionality, and triggers the
worsening of negative symptoms of the disease. Given
that LPS administration emulates the noxious inﬂuence
of a peripheral inﬂammatory condition, these results are
particularly important for patients that suffer from
ocular neurodegenerative diseases such as glaucoma,
diabetic retinopathy, RP, or macular degeneration.
According to these results, peripheral damage, such as a
systemic infection or chronic inﬂammatory process,
could accelerate the progression of the disease and
should be considered when selecting an appropriate
therapy to revert, block or slow-down the degenerative
process.
Neurodegenerative diseases share common pathogenic
mechanisms, including neuroinﬂammation. In this sense,
the activation of microglial cells has been extensively
reported in both retinal and brain diseases3,79. On the
other hand, it has been previously shown that systemic
conditions can worsen and exacerbate the symptoms of
chronic neurodegeneration in degenerative diseases as
Parkinson’s and Alzheimer’s disease, accelerating the
progression of the disease40,80–83. Therefore, our results
suggest a possible harmful effect of systemic inﬂammation
on the progression of retinal degenerative diseases that
could be extrapolated to brain neurodegenerative dis-
orders, such as Parkinson’s or Alzheimer’s diseases.
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